An Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of Aripiprazole Long-acting Injectable Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder
收藏DataCite Commons2025-09-09 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011630/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The primary objective of this trial is to evaluate the pharmacokinetics (PK) of aripiprazole long-acting injectable (LAI) (420 mg) following deltoid or gluteal muscle administration in adult subjects with schizophrenia or bipolar I disorder.
提供机构：
Vivli
创建时间：
2025-07-14
